Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash from Operations (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Cash from Operations for 12 consecutive years, with 257000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 85.33% year-over-year to 257000.0, compared with a TTM value of 6060000.0 through Sep 2025, up 47.59%, and an annual FY2024 reading of 9600000.0, up 37.23% over the prior year.
  • Cash from Operations was 257000.0 for Q3 2025 at Arcadia Biosciences, up from 2033000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 257000.0 in Q3 2025 and bottomed at 8268000.0 in Q3 2021.
  • Average Cash from Operations over 5 years is 3613105.26, with a median of 3365000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations plummeted 75.93% in 2023, then soared 85.33% in 2025.
  • Year by year, Cash from Operations stood at 6692000.0 in 2021, then surged by 64.79% to 2356000.0 in 2022, then plummeted by 75.93% to 4145000.0 in 2023, then skyrocketed by 47.36% to 2182000.0 in 2024, then soared by 88.22% to 257000.0 in 2025.
  • Business Quant data shows Cash from Operations for RKDA at 257000.0 in Q3 2025, 2033000.0 in Q2 2025, and 1588000.0 in Q1 2025.